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The aim of the study was to evaluate the effects of an acute increase in triglyceride levels induced by Intralipid (Kabivitrum'
Stockholm, Sweden) infusion on forearm glucose uptake, glucose oxidative metabolism, and hepatic glucose production
independent of circulating free fatty acid {FFA) levels in man. Six normal subiects underwent three different tests in random
order. Each test consisteú of a conirol period of 120 minutes followed by a euglycemic, hyperinsulinemic clamp lasting 120
minutes. ln test 1. a high-dose intravenous lntralipid infusion was performed to increase triglyceride and FFA levels' In test 2'
heparin (30 U/min) plus low-dose lntralipid infusions were performed to maintain triglyceride at normal levels and increase
only FFA levels. Test 3 was performed as a control study. During the 120-minute control period, forearm glucose uptake and
hepatic glucose production were not affected by increasing only FFA levels (test 2) or FFA and triglyceride levels {test 1} as
compared with the control study. On the contrary, glucose oxidation was significantly decreased as compared with the control
study during tests î and 2, without a further significant decrease during simultaneously increased FFA and triglyceride levels'
Concomitanìly, lipid oxidation was similar in tests 1 and 2, at values significantly greater than in test 3' During the euglycemic
clamp, forearm glucose uptake and glucose oxidation were significantly lower during tests 1 and 2 than test 3' At variance with
the control period, the increase of triglyceride levels during test 1 caused a significant 30% to 407o decrease of both parameters
as compared with test z. Opposite results were found for lipid oxidation, which remained unchanged during test I as compared
with the control period bui significantly decreased during tests 2and3. Hepatic glucose production was less inhibited during
test 1 than during tests 2 and 3, and less so during test 2 than test 3. In conclusion, at least under these particular conditions,
acute hypertriglyceridemia induced by Intralipid infusion seems to decrease forearm glucose uptake, glucose oxidation, and
insulin-induced suppressibility of hepatic glucose production. Taking our results together, it seems that the triglyceride effect
on carbohydrate metabolism-occurs via triglyceride hydrolysis using the intracellular pathways of FFA without interference
with the circulating FFA Pool.
Copyright a 1995 hy W.B. Saunders Company
INSULIN RESISTANCE and hypertriglyceridemia are
I strictly interrelated to such a degree that several investi-
gators1.2 have suggested the existence of a syndrome (syn-
drome X, or insulin-resistance syndrome) characterized by
hyperinsulinemia, hypertriglyceridemia, hypertension, coro-
nary artery disease, insulin resistance, and impaired glucose
tolerance. Although there is much evidence suggesting that
hypertriglyceridemia is a consequence of insulin resistance,
little is known about the effects of triglycerides on insulin
sensitivity. Previous studies have shown that in normal
subjects, impaired-glucose tolerance subjects, and non-
insulin-dependent diabetes mellitus (NIDDM) subjects,
there is an inverse relationship between triglyceride levels
and insulin sensitivity.3'4 Epidemiologic data indicated that
insulin resistance precedes the development of hypertriglyc-
eridemia. In addition, insulin stimulates triglyceride very-
low-density lipoprotein synthesis,3 and long-term therapy
with gemfibrozil improves glucose tolerance and insulin
levels during oral glucose tolerance tests in subjects with
severe hypertriglyceridemia.5 Recently, Yki-Jarvinen and
Taskinen6 and Widen et al7 have shown that hypertriglyceri-
demic NIDDM patients are more insulin-resistant than
matched nonhypertriglyceridemic patients. On the other
hand, a reduction in triglyceride levels via gemfibrozil or
bezafrbrate therapy did not improve insulin sensitivity in
mildly hypertriglyceridemic NIDDM patients or in hypertri-
glyceridemic patients.8'e
The aim of this study was to evaluate the effects of acute
hypertriglyceridemia on forearm glucose uptake, glucose
oxidation, and hepatic glucose production in man. To the
best of our knowledge, the only way to produce an acute
increase in triglyceride levels is to use an Intralipid infu-
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sion.10,11 However, since this also increases free fatty acid
(FFA) levels,12'13 it could become impossible to discrimi-
nate between the efiects of FFA and those of triglycerides
on glucose metabolism. On the other hand, it is also
possible to increase FFA levels without changing triglycer-
ide levels by using heparin infusion with or without low-
dose Intralipid (Kabivitrum, Stockholm, Sweden).14'15 There-
fore, we designed a study in which both FFA and triglyceride
levels or only FFA levels were increased. Thus' by compar-
ing results, we were able to calculate the efiects of triglycer-
ides on glucose metabolism.
SUBJECTS AND METHODS
The protocol of the study was approved by the local Ethics
Committee, and written informed consent was obtained from all
subìects. Sir normal men (mean + SE: age, 27.7 + 0.9 years; body
mass index, 24.5 ! 0.7 kg/m2; weight, 80.1 t 4.5 kg; fat-free mass
[FFM],60.8 + 2.6kg; and fat mass, 19.2 + 2;7 kg)were admitted to
the metabolic unit in the morning after an overnight fast. Subjects
were nonsmokers and were taking no medication. Each subject
underwent three different tests in random order, with at least a
15-day interval between t'rr'o consecutive tests. Test 1 was designed
to increase triglyceride and FFA levels, test 2 to increase only FFA
levels, and test 3 as a control study. Each test consisted of a control
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period of 120 minutes followed by a euglycemic, hyperinsulinemic
clamp lasting 120 minutes, combined with Intralipid 20% (2.5
ml-/min) intravenous infusion (test 1), heparin (30 U/min) plus
Intralipid 20% (0.5 ml-/min) infusions (test 2), or saline infusion
(test 3). Test 1 and test 2 were preceded by a 250-U heparin
intravenous bolus (Fig 1). Five pilot studies were performed to
determine optimal rates of Intralipid and heparin infusions to
achieve target triglyceride and FFA levels (data not shown). The
euglycemic, hyperinsulinemic clamp consisted of a continuous
insulin (25 mu/kg/h) infusion test lasting 120 minutes, with blood
glucose levels maintained at basal values via a variable glucose
(20%) infusion.t6 Changes in glucose infusion were made accord-
ing to measurements obtained every 5 minutes from a glucose
analyzer (Yellow Springs Instrument, Yellow Springs, Fullerton,
OH). On the morning of each test, a 20-gauge plastic cannula
(Abbocath T; Abbot, Ireland, Sligo, Republic of Ireland) was
inserted in a dorsal vein of one hand in a retrograde position, and
the hand was placed in a Plexiglas box and maintained at 55'C for
intermittent sampling of arterialized blood. An 18-gauge plastic
cannula was inserted into a large antecubital vein of the same arm
for infusions, and another 18-gauge plastic cannula was inserted in
a retrograde position into a large, deep antecubital vein of the
contralateral arm for intermittent sampling of deep venous fore-
arm blood.
Blood flow of the proximal forearm was determined at each
blood sampling using venous-occlusion plethysmography (control
period: 105, 110, 115, and 120 minutes; clamp period: 225, 230,235,
and 240 minutes), with a collecting pressure of 60 mm Hg and a
wrist-occlusion pressure of 220 mm Hg inflated simultaneously.
Each measurement is the mean of a minimum of four occlusions.
with a range of coefficient of variation (CV) values from 4.39Vo to
7 .06%. The CV of the eight blood-ffow measurements performed
during the final 30 minutes of the control and clamp periods of
each study was calculated as an index of intrastudy variability.
During the control period, mean CVs were 3.8 + 0.6%,6.6 + 1.4%,
and 4.8 + 1.37o, respectively, during tests 1, 2, and 3; during the
clamp period, mean CVs were 5.9 + 7.670,1.7 + 0.8%, and 6.0 +
l.3Vo, respecfively, during tests 1, 2, and 3. Changes in forearm
volume were measured using a temperature-compensated mer-
cury, rubber strain gauge placed distally to the tip of the cannula.lT
The wrist cuff was inflated to 220 mm Hg 3 minutes before and
duríng venous sampling, to exclude hand blood flow from forearm
measurement. Calibration of the apparatus was made immediately
after venous sampling. Blood flow was determined as milliliters per
minute per 100 mL forearm volume tissue. Forearm circumference
CONTROLPERIOD I EUGL CLAMPPERIOD
6,6- zH2 giucose 5mg&g + 0.05 mgkElnrtn
test 1: Intralipid 207o (2.5 ml/mn)
test 2: Heparin 30 U/min+Intralipid ZOVo (0.5 mllmin)
test 3: Saline infusion
+
I
Heprin 250 U
(test 1 md test 2)
Fig 1. Study design. *Arterialized venous samples. lC, indirect
calorimetry; EUGL, euglycemic.
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was measured at the proximal and distal borders of the plethysmog-
raphy cufÌ, and the contained volume was calculated using the
equation of a truncated cone. All measurements of total blood flow
were less than 4.0 mll100 mL forearm/min, and we have therefore
used the following equation for estimation of forearm muscle blood
flow (FMBF) in milliliters per 100 mL forearm per minutels:
FMBF : 0.47 (tofal forearm blood flow) * 0.83. Forearm uptake
or release of glucose and metabolites (lactate, pyruvate, B-OH-
butyrate, alanine, and citrate) was calculated in the following
manner: (arterialized venous blood concentration 
- 
deep venous
blood concentration) x FMBF. Plasma glucose values were con-
verted to whole-blood values by multiplying plasma values by
[1 - (0.37 x hematocrit)]. In each study, arterialized and deep
venous sampling were obtained simultaneously for glucose, metabo-
lites, FFA, and triglycerides at 105, 110, 115, and 720 minutes
before the clamp and 225,230,235, and 240 minutes during the
clamp.
FFM and fat mass were calculated using the equation reported
by Heymsfield et al,re which takes into account midarm circumfer-
ence and abdominal and triceps skinfold thickness.
The total glucose disposal rate was evaluated isotopically using a
primed (5 mg/kg)-continuous (0.05 mg/kg/min) infusion of [6,6-
2H2] glucose. During the clamp period, blood glucose was kept
constant by means of a variable infusion of 20Vo dexfrose. A fixed
amount of dideuterated glucose was also added to the glucose bag
(1A% of cold glucose) to keep isotopic enrichment constant.20 The
rate of appearance of unlabeled glucose was calculated using
Steele's model,21 taking into account the nonnegligible mass stable
isotope in the way indicated by Cobelli et a1.22 Rates of hepatic
glucose production were calculated by subtracting the rate of
exogenously infused glucose (M value) from the isotopically
measured rate of disappearance of the tracer.
To address better the point of whether triglyceride effects are
independent from the circulating FFA pool, we evaluate palmitate
turnover using a continuous infusion of [1-13C]palmitate (0.06
pmol/kg/min) throughout the three test periods. In fact, palmitate
is the second most abundant FFA in plasma, and its fractional
turnover rate is representative of the total FFA pool.
During the last 30 minutes (control and euglycemic clamp
periods), rates of glucose (G6y) and lipid (Lea) oxidation were
calculated at 1-minute intervals using indirect calorimetry (Delta-
trac; Datex, Helsinki, Finland), which measured oxygen uptake
(Vco2) and carbon dioxide production (Vco2). The following
equations were used23:Gsr : 4.55Vcoz 
- 
3.21Yo2 
- 
2.87N, and
Lox : 1.67Vco2 
- 
1.67vco2 
- 
1.92N. Protein oxidation was
calculated by multiplying urinary N excretion by 6.2524 and normal-
ized by urea clearance.24 The urinary nitrogen excretion rate was
calculated by collecting urine samples throughout the test.
Assays
All samples were assayed for metabolites and insulin in a single
assay. In particular, serum insulin (intraassay CV 3.0%, interassay
CV 5.0%) was measured by radioimmunoassay using commercial
kits.
Samples for metabolites were collected into weighted tubes
containing chilled 0.5-mol/L perchloric acid. Blood B-OH-butyrate
(intraassay CY 3.ÙVo, interassay CV 10.0%), glycerol (intraassay
CV 3.0%, interassay CV 3.0%), lactate (intraassay CY 4.07o,
interassay CV 7 .57o), pyruvafe (intraassay CV 8.0%, interassay CV
9.5%), and alanine (intraassay CV 6.07c, interassay CV 10.0%)
were assayed using automated enzymatic spectrofluorimetric meth-
ods adapted to a Cobas Fara II analyzer (Hoffman-La Roche,
Basel, Switzerland25), whereas plasma FFA (intraassay CV 3.0%,
interassay CV 3.0%) and serum triglyceride levels were measured
using an automated enzymatic spectrophotometric technique
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adapted to the Cobas Fara II. Citrate levels were assayed using a
commercial kit (Boehringer-Mannheim, Milan, Italy) with the
following changes to adapt the method to a Cobas Fara II. The
solution was diluted 1:150 with distilled water; the final concentra-
tion of NADH was 0.04 mg/ml, malate dehydrogenase 0.90
U/mL, and lactate dehydrogenase 1.86 U/mL. For each sample,
0.04 U citrate lyase was added to start the reaction. The following
standard concentrations were used: 0,32.5,65.06,130.1, and 260.2
pmol/L. Standards and samples were prepared by adding 1 mL
perchloric acid 3Vo to 1 mL of samples and neutralized by 0.5 mL
0.3-mol/L KzCO3. The intraassay CV was 3.0V0, and the interassay
CV was 6.0Vo. Alanine plasma levels were assayed with an
o-phthaldialdehyde precolumn derivatization reaction followed by
high-performance liquid chromatography analysis on an RP-C18
column and fluorometric detection.26
Isotopic enrichment of [6,6-2H2]glucose was measured using the
gas chromatographic-mass specttometric method previously re-
ported.27 Weighed amounts of [1-13C]palmitic acid (99 atom
percent excess [APE]) were bound to fatty acid-free human
albumin (ORHA, Behring, Germany), and the solution was then
filtered through a 0.8- and a 0.22-pm sterile filter before infusion to
human subjects. Palmitic acid levels and enrichment were deter-
mined after plasma extraction, using heptadecanoic acid as inter-
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nal standard and methylation of the crude extracts with diazometh-
ane, and the samples were then analyzed by gas chromatography-
mass spectrometry. Details of the method are reported by Magni et
a1.28
Statistical Analysis
Each variable is expressed as the mean + SE at each time
interval. Comparisons between experiments were made by means
of two-way ANOVA followed by Student's I test for paired data. P
values less than .05 were considered statisticallv sisnificant.
RESULTS
Control Peiod
Anerialized levels. During test 1, triglyceride and FFA
levels achieved a plateau at3.9 + 0.5 and 1..7 + 0.3 mmol/L,
respectively, whereas during test 2, triglyceride and FFA
ievelswere 0.8 + 0.2 and 1.8 + 0.2, respectively (P < .05 for
triglyceride levels, NS for FFA levels). In test 3, triglycer-
ides and FFA remained at basal levels (Fig 2).
B-OH-butyrate and glycerol levels were significantly
higher in test 1 than in tests 2 and 3, and higher in test 2
8.00
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Fig 2. Blood glucose, serum insulin, serum triglyceride, and plasma FFA levels during control and clamp periods (mean + SE). (!) Test 1,
increased FFA and triglyceride levels; (.) test 2, increased FFA levels; (Al test 3, control study.
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than in test 3 (Table 1). The different Intralipid and
heparin infusions used to achieve target triglyceride and
FFA levels produced significant differences in glycerol
levels during test 1 and test 2, since it is well known that the
Intralipid 20Va emulsion contains 22.5 911.,000 mL of
glycerol.
Citrate, lactate, and alanine levels were similar during
the three tests. Pyruvate levels were significantly decreased
during tests I and2 as compared with test 3 (Table 1).
Forearm glucose uptake and metabolite balance. Fore-
arm glucose uptake was not affected by increasing only FFA
levels or both FFA and triglyceride levels as compared with
the control study (Table 2). Similarly, forearm citrate and
alanine release and blood flow were similar during the
three tests (Table 2). In contrast, forearm B-OH-butyrate
uptake was significantly greater during tests 1 and 2 versus
test3(P<.05).
Glucose and palmitate metabolism. Glucose turnover
and hepatic glucose production were similar during the
three tests (Table 3). Palmitate turnover rate was signifi-
cantly greater during tests I and 2 versus test 3 (test 1,
2.32 + 0.47: test 2, 2.48 * 0.33; and test 3, 1.28 * 0.18
p"mol/kg FFM/min; P < .05). No significant difierences
were seen between test 1 and test 2.
Oxidative metabolism. Glucose oxidation rate was signifì-
cantly lower during tests 1 and 2 versus test 3 (Table 3). The
increase of triglyceride levels obtained during test 1 did not
cause any further significant decrease in oxidative glucose
disposal as compared with test 2. Lipid oxidation rate was
similar in tests 1 and2, with values twofold gteater than in
test 3 (Table 3). Protein oxidation rate was similar during
the three studies (not shown).
Clamp Period
Arteialized levels. Blood glucose was successfully
clamped in all tests, with a CV of less than 57o. Insulin
levels achieved a plateau at192 + 12,204 + 24, and234 +
\2 pmollL during tests 1,2, and 3, respectively (NS; Fig 2).
Table 1. Blood Metabolite Levels (pmol/L) During Control and
Euglycemic, Hyperinsulinemic Clamp Periods in Six Subiects
(mean + SE)
Parameter Test 1 Test 2 Test 3
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Table 2. Forearm Glucose Uptake and Metabolite Balance During
Control and Euglycemic, Hyperinsulinemic Periods in Six Subiects
(mean + SE)
Parameter Test'1 Test 2 Test 3
Control
Glucose uptaket
g-OH-butyrate uptake
Lactate release
Pyruvate uptake
Alanine release
FMBF+
Clamp
Glucose uptakeî
FFA uptake
Triglyceride uptake
p-OH-butyrate uptake
Lactate release
Pyruvate uptake
Alanine release
FMBF*
0.25 + 0.02
0.54 + 0.12
0.03 + 0.01
0.10 + 0.1 1
0.02 + 0.00
0.12 + O.O2
2.49 + 0.07
0.46 + 0.065
0.02 + 0.00
0.14 + 0.05
0.23 + 0.18q
0.03 + 0.00
0.01 + 0.01
0.01 + 0.01
0.03 + 0.055
2.46 + 0.09
0.47 + 0.11
0.3'l + 0.03
0.02 + 0.00
0.04 + 0.01
0.02 + 0.01
0.06 + 0.01
2.51 + 0.10
0.86 + 0.14+5
0.02 + 0.00
0.01 + 0.00f
0.08 + 0.025
0.02 + 0.00f
0.10 + 0.05
0.02 + 0.01
0.06 + 0.04
2.40 + 0.08
0.41 + 0.06
0.03 + 0.01 |
0.03 + 0.01
0.21 + 0.13
0.02 + 0.03
0.13 + 0.02
2.43 + O.O7
1.86 + 0.348
0.00 + 0.00
0.01 + 0.01+
0.02 + 0.00+
0.01 + 0.01f
0.03 + 0.07
0.01 + 0.01
0.13 + 0.02
2.46 + 0.06
*mL/100 mL/min.
tpmol/100 mL/min.
fP<.05vtest1.
5P < .05 v control period.
lP < .05 vtests 1 and 2.
Triglyceride levels remained significantly higher during test
1 as compared with tests 2 and 3. In contrast, FFA levels
were similar between tests 1 and 2, but significantly higher
than in test 3 (Fig 2).
By the simultaneous increase of FFA and triglyceride
levels (test 1), B-OH-butyrate remained at levels found in
the control period, with values approximately 10- and
100-fold those achieved during tests 2 and 3. During both
tests 2 and 3, B-OH-butyrate levels significantly decreased
as compared with control levels, remaining significantly
elevated during test 2 as compared with test 3 (Table 1).
During tests 1 and 2, due to the exogenous Intralipid
infusion, glycerol levels were maintained at control levels
(Table 1).
No significant difierences were found for citrate, lactate,
pyruvate, and alanine levels among the three tests (Table 1).
Foreann glucose uptake and metabolite balance. Fore-
arm glucose uptake significantly increased during all tests
as compared with each control-period level (Table 2). The
Table 3. Glucose and Oxidative Metabolism During Control Period in
Six Healthy Subiects (mean + SE)
Parameter Test 1 Test 2 Test 3
Control
Glycerol
fl-OH-butyrate
Citrate
Lactate
Pyruvate
Alanine
Clamp
Glycerol
f3-OH-butyrate
Citrate
Lactate
Pyruvate
Alanine
373.7 + 57.3
1,102 + 245
78.6 * 18.0
561.2 + 46.4
39.4 * 4.4
246.8 + 26.0
364.9 + 53.'l
1,495 + 461
93.0 + 20.7
620 + 62*
47.7 + 6.6
'191.1 + 26.6x
59.5 + 7.8t
434.8 + 60.5t
92.4 + 17.4
508.2 + 62.8
34.6 + 4.6
242.3 + 26.0
58.1 + 18.6t
174 + 38"î
81.3 + 9.9
525 + 60"
42.8 + 5.6
205.0 + 27.6+
15.9 + 2.71
55.1 + 11.5+
66.9 + 16.5
531.8 + 62.8
61.5 + 11.0
302.3 + 37.9
1.1 + 0.4*î
'13.0 + 2.5*+
44.1 + 13.51
580 :t 46+
61.2 + 5.3
267.8 + 28.8*
Glucose disposal rateî
APE (90-120 min)
CV of APE (%)
Hepatìc glucose
productionî
Glucose oxidationt
Lipid oxidationî
15.48 + 0.93 15.24 + 0.97 14.47 + 0.72
2.43 + 0.18 2.40 + 0.18 2.48 + 0.11
3.3 + 0.8 4.9 + 1.2 3.0 + 0.6
15.48 + 0.93 15.24 + 0.97 14.47 * 0.72
4.44 + 0.79 5.95 t: 0.86 12.19 + 0.95*
6.23 a 0.38 5.84 + 0.29 3.23 + 0.23*
*P < .05 v control period.
tP < .05 vtest 1.
+P < .05 vtests 1 and 2.
*P < .05 vtests 1 and 2.
tpmol/kg FFMi min.
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increase of FFA levels in the presence of normal triglycer-
ide levels (test 2) significantly decreased forearm glucose
uptake as compared with test 3. Interestingly and at
variance with the control period, the simultaneous increase
of triglyceride and FFA levels (test 1) caused a significant
decrease in forearm glucose uptake as compared with test 2
(Fig 3).
Forearm FFA and B-OH-butyrate uptakes were similar
during tests 1 and 2, and were completely suppressed
during test 3. In contrast, forearm triglyceride uptake and
forearm citrate release were significantly greater during test
1 than during tests 2 and 3 (Table 2). Blood flows were not
significantly modified (Table 2).
Glucose and palmitate metabolism. Glucose turnover
rate was superimposable during tests 1 and 2, but signifi-
cantly lower than during test 3 (Table 4).
At high triglyceride and FFA levels (test 1), hepatic
glucose production was significantly less inhibited than
during tests 2 and 3. As expected, also during test 2, hepatic
glucose production was less inhibited than during test 3
(Table 4).
Once again, palmitate turnover rate was significantly
greater during tests 1 and 2versus test 3 (test 1,2.71 + 0.29;
test 2,2.09 + 0.35; and test 3, 0.39 + 0.03 prmol/kg FFM/
min; P < .001). No significant diflerences were seen be-
tween test 1 and test 2.
Oxidative metabolism. Glucose oxidation rate increased
in all tests as compared with control-period ievels. The
increase of FFA levels (test 2) caused a significant decrease
in glucose oxidation rate as compared with test 3. By also
increasing triglyceride levels (test 1), we were able to
demonstrate a further significant decrease of glucose oxida-
tion rate as compared with test 2 (-îable 4).
Lipid oxidation rate was significantly greater during test 1
versus tests 2 and 3, and during test 2 versus test 3 (Table 4).
Protein oxidation rate was similar during the three studies,
without significant changes as compared with the control
oeriod.
DISCUSSION
The study was designed to quantiff the effects of in-
creased triglyceride levels on glucose metabolism indepen-
Table 4. Glucose and Oxidative Metabolism During Clamp Period in
Six Healthy Subiects (mean + SEI
Parameter Test 1 Test 2
dent of circulating FFA levels. For this reason, Intralipid or
heparin was infused to increase both triglyceride and FFA
levels in one test, and only FFA levels in the other test.
Therefore, for the first time, we were able to analyze the
effects of an acute increase in triglyceride levels on glucose
metabolism in man. In the past, the effects of a concomitant
increase in triglyceride levels by infusing Intralipid to study
the effects of FFA on the Randle cycle2e were never taken
jn16 29961n1. 12,13,30,3 I
In the present study, forearm glucose uptake, glucose
oxidation, and hepatic gÌucose production were signifi-
cantly decreasedby 75%,80Vo, and33Vo úring test 1 (high
triglyceride and FFA levels) and only by 54Vo,55Vo, and
567o drning test 2 (high FFA levels). [1-t3C]palmitate
turnover rate was similar during tests I and 2, confirming
that the effect of hypertriglyceridemia on glucose metabo-
lism was independent of the circulating FFA pool. On the
contrary, the findings of a higher release of citrate from
muscle and higher B-OH-butyrate levels when triglyceride
and FFA levels were both increased (test 1) supports the
hypothesis that the intracellular fate of triglycerides and
FFA was the same. In fact, we might postulate that the
triglyceride hydrolysis increased the intracellular FFA pool,
which in turn enhanced B-oxidation and decreased glucose
utilization. Another point that validates this hypothesis was
the fìnding of lipid oxidation being significantly increased by
1.5Vo dr;ring test 1 as compared with test 2.
Taking our data together, we might postulate that during
Intralipid infusion, at least 257o oî the total decrease of
forearm glucose uptake and glucose oxidation is related to
hypertriglyceridemia.
The results of the present study are indirectly supported
when comparing two previous experiences in which only
heparin (increase in FFA levels alone32) or Intralipid
(simultaneous increase in FFA and triglyceride levels13)
were infused during a euglycemic, hyperinsulinemic clamp.
Although FFA levels were 0.6 mmol/L in both tests,
glucose oxidation was reduced by 24% in one study32 and by
357o in the other study.13 In agreement with our findings
that triglyceride effects on carbohydrate metabolism are
independent of the circulating FFA pool, Huttunen et al33
have demonstrated that the utilization of very-low-density
lipoprotein FFA increased the intracellular but not the
plasma FFA pool. On the other hand, Dagenais et al,3a
Groop et al,32 and Bonadonna et al,3s using [1-1aC]palmitate
as a tracer of the circulating FFA pool combined with
indirect calorimetry, have shown that plasma FFA ac-
counted îor 20Va fo 50Vo of total lipid oxidation in skeletal
muscles. In contrast, plasma triglyceride oxidation was at
\east 307o of total lipid oxidation in rats.36 These data are in
agreement with our findings of a 15Vo increase in lipid
oxidation and a 25Vo decrease in glucose oxidation when
triglyceride levels were increased in test 1.
Another point that needs to be discussed is at which
peripheral levels triglycerides can influence glucose metabo-
lism. There is some evidence that hypertriglyceridemic
NIDDM subjects (plasma triglyceride levels between 3 and
18 mmol/L) are more insulin-resistant than NIDDM
matched subjects without hypertriglyceridemia,6'7 and that
Test 3
Glucose disposal rate* 19.40 + 1.59 19.70 + 1.38
M value* 11.39 + 1.09 14.54 + 0.88î
APE (2'10-240 min) 2.62 + 0.15 2.70 + 0.13
CV of APE (%) 3.5 + 0.9 4.3 * 1.2
Hepatic glucose
production* 8.01 + 1.08 5.16 + 0.721
Glucose oxidation* 5.08 + 1.21 7.68 + '1.29î
Lipid oxidation* 6.15 + 0.43 5.20 + 0.221
25.31 + 1.66+
24.72 + 1.51t
2.62 + 0.14
3.3 + 0.6
0.59 + 0.67+
19.2 + 1.71+
1.26 + 0.31f
NOTE. IVI value is the glucose infusion rate during the last 30 minutes
of the clamp.
*pmol/kg FFM/min.
tP < .05 y test 1.
+P < .05 y tests 1 and 2.
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long-term treatment with gemfibrozil improves insulin sen-
sitivity in severely hypertriglyceridemic subjects.s In the
present study, insulin sensitivity was decreased when triglyc-
eride levels reached 6 mmol/L in normal subjects. On the
contrary, in mildly hypertriglyceridemic NIDDM subjects
(plasma triglyceride levels 
- 
1.8 mmol/L), 12 weeks of
therapy with gemfibrozil decreased triglyceride levels by
42% brt did not improve hemoglobin A16 and fasting
glucose levels or glucose and FFA turnover and oxidation.q
Taking all these results together, we can postulate that
triglycerides play some role in glucose metabolism only
when their levels are increased to 5 mmol/L. Below this
level, the intracellular feedback mechanism regulating FFA
oxidation, recently demonstrated by Yki-Jawinen et a1,37
could also modulate triglyceride utilization. However, evalu-
ation of the effects of incremental triglyceride levels on
glucose metabolism was beyond the scope of the present
study and requires further investigation.
For measuring forearm metabolite balance, we used the
arterialized-deep venous difference instead of the classic
arterial-deep venous difference. This method is widely
accepted as a substitute for true arterial blood.l4'31'32 To
heat the hand, we used a warm-air box, and the arterialized
oxygen saturation was between 917o and 98% (mean I SE,
PIATTI ET AL
95.1% + 0.3%).ln addition, deep venous oxygen saturation
did not significantly change before and during the heating
period in all tests (before heating, 58.4Va + 0.9Vo; at the
end of the control period, 56.9Va + l.8Vo; at the end of the
clamp,6l.6Vo + l.9Vo; NS). Our results confirm the study3s
in which deep venous oxygen saturation remained un-
changed when a correct occlusion period for the hand
circulation was maintained. Different results were found by
Astrup et al3e and Liu et al,a0 who showed that deep venous
oxygen saturation of the contralateral heated hand signifi-
cantly increasedby 9%, but this fact is probably related to
the difierent duration of the hand occlusion. Whereas in
our study we maintained hand occlusion for 3 minutes,
Astrup et a13e maintained it for 1 minute and Liu et ala0 did
not occlude hand circulatron.
In conclusion, at least under these particular conditions,
acute hypertriglyceridemia induced by Intralipid infusion
seems to decrease forearm glucose uptake, glucose oxida-
tion, and insulin-induced suppressibility of hepatic glucose
production. The triglyceride effect on carbohydrate metabo-
lism seems to follow the same intracellular pathway of FFA,
since triglyceride hydrolysis might increase the intracellular
FFA pool without interference with the circulating FFA
oool.
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